NCT03229499

Pulmonary Hypertension and Anastrozole Trial

Pulmonary Hypertension and Anastrozole Trial (PHANTOM)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in pulmonary arterial hypertension (PAH).

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	Anastrozole	Anastrozole is an aromatase inhibitor indicated for: * adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer * first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer * treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
DRUG	Placebo Oral Tablet	matching placebo tablet

Timeline

• Start date: 2017-12-07
• Primary completion: 2022-07-22
• Completion: 2022-07-22
• First posted: 2017-07-25
• Last updated: 2024-05-01
• Results posted: 2024-05-01

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study